Will Advanced Radiotherapy Demand Propel the Global Linear Accelerators Market at 10.4% CAGR? According to a new report from Intel Market Research, the global Linear Accelerators for Radiation market was valued at USD 3.69 billion in 2026 and is projected to reach USD 7.26 billion by 2034, growing at a robust CAGR of 10.4% during the forecast period (2026–2034). The escalating worldwide incidence of cancer is a primary driver for the demand for advanced radiotherapy solutions. These devices are fundamental in modern oncology for delivering precise external beam radiation treatments to a growing patient population. Meanwhile, the improvement of healthcare access in developing regions further stimulates this demand, as public and private entities increasingly invest in upgrading their cancer treatment capabilities. https://www.intelmarketresearch.com/download-free-sample/16454/linear-accelerators-for-radiation-market

What Is the Future of Brachytherapy Afterloaders? Growth Forecasts According to a newly published market research report by 24LifeSciences, global brachytherapy afterloaders market was valued at USD 92.2 million in 2024 and is projected to reach USD 102 million by 2031, growing at a compound annual growth rate (CAGR) of 1.5% during the forecast period 2025-2031. A brachytherapy afterloader is a sophisticated medical device used to deliver targeted internal radiation therapy for cancer treatment. These systems are the technological backbone of modern brachytherapy, automating the precise placement and removal of radioactive sources directly inside or next to tumors. This targeted approach minimizes radiation exposure to healthy surrounding tissues and medical staff while delivering highly concentrated radiation doses to cancerous cells. These devices are critically important in treating prostate, gynecological, breast, and other cancers where precise radiation delivery is essential for optimal patient outcomes. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/6426/brachytherapy-afterloaders-market-market-market

Top 7 Innovations in Targeted Therapy for Malignant Glioma According to a newly published market research report by 24LifeSciences, Global Malignant Glioma Therapeutic Market was valued at USD 4.8 Billion in 2025 and is projected to grow from USD 5.1 billion in 2026 to reach USD 8.2 Billion by 2034, growing at a compound annual growth rate (CAGR) of 7.2% during the forecast period. Malignant gliomas, particularly glioblastoma multiforme (GBM), represent some of the most aggressive and lethal primary brain tumors. These cancers are characterized by their rapid proliferation, invasive nature, and profound neurological devastation. The standard of care has long involved a multidisciplinary approach including maximal safe surgical resection, radiotherapy, and chemotherapy, with temozolomide serving as the chemotherapeutic backbone. However, the treatment landscape is rapidly evolving beyond these conventional modalities. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9028/malignant-glioma-therapeutic-market

What Is the Future of Solid Tumor Therapeutics? Growth Forecasts According to a newly published market research report by 24LifeSciences, global solid tumor therapeutics market was valued at USD 129.83 billion in 2025 and is projected to grow from USD 141.83 billion in 2026 to reach USD 237.04 billion by 2034, growing at a compound annual growth rate (CAGR) of 9.2% during the forecast period. Solid tumor therapeutics are treatments designed to target and eradicate abnormal masses of tissue that do not contain cysts or liquid areas. These therapies are a cornerstone of oncology, addressing a wide range of cancers that manifest as solid masses, such as those found in the breast, lung, prostate, and colon. The therapeutic landscape includes several key modalities, primarily chemotherapy, hormone therapy, immunotherapy, and targeted therapy, each with distinct mechanisms of action. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9242/solid-tumor-therapeutics-market

Top 10 Companies Leading the Targeted Drug Delivery System Market According to a newly published market research report by 24LifeSciences, global targeted drug delivery system market was valued at USD 178.1 billion in 2025 and is projected to grow from USD 193.8 billion in 2026 to reach USD 324.7 billion by 2034, growing at a compound annual growth rate (CAGR) of 8.5% during the forecast period. Targeted drug delivery systems represent a transformative approach in modern therapeutics, designed to transport pharmaceutical agents precisely to specific diseased sites within the body while minimizing exposure to healthy tissues. These advanced systems utilize sophisticated carriers such as liposomes, nanoparticles, and monoclonal antibodies to enhance drug efficacy, improve patient outcomes, and reduce systemic side effects. The technology has become particularly vital in treating complex conditions like cancer, autoimmune disorders, and neurological diseases, where precision is paramount for therapeutic success. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8708/targeted-drug-delivery-system-market

AI & Molecular Diagnostics Reshaping Cervical Cancer Screening Market According to a newly published market research report by 24LifeSciences, global cervical cancer diagnostic testing market was valued at USD 6.19 billion in 2025 and is projected to grow from USD 6.47 billion in 2026 to reach USD 8.44 billion by 2034, growing at a compound annual growth rate (CAGR) of 4.6% during the forecast period. Cervical cancer diagnostic tests are essential medical procedures designed to detect precancerous and cancerous conditions in the cervix. These tests are critical for early intervention because cervical cancer is primarily caused by persistent infection with high-risk human papillomavirus (HPV) strains. The primary diagnostic modalities include Pap smear tests (Pap cytology), HPV DNA tests, colposcopy, and cervical biopsies, which are fundamental components of routine gynecological screening programs worldwide. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9355/cervical-cancer-diagnostic-testing-market

Stem Cell Banking Market Growth Analysis: Opportunities & Forecasts According to a newly published market research report by 24LifeSciences, global stem cell banking market was valued at USD 1,761 Million in 2025 and is projected to grow from USD 1,896 million in 2026 to reach USD 2,943 Million by 2034, growing at a compound annual growth rate (CAGR) of 7.8% during the forecast period. Stem cell banking is the process of collecting, processing, and cryogenically preserving stem cells from sources like umbilical cord blood, cord tissue, and adult tissues for potential future therapeutic use. This service, often termed a biological insurance policy, plays an increasingly crucial role in regenerative medicine, offering potential treatments for a wide array of conditions from blood cancers like leukemia and lymphoma to genetic disorders and potential future applications in neurological and autoimmune diseases. Its importance is underscored by the growing arsenal of stem cell-based therapies entering clinical practice. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/4282/stem-cell-banking-market-market

Hydroxycarbamide Market’s CAGR of 6.1%: Leaders in Oncology & Hematology According to a newly published market research report by 24LifeSciences, global hydroxycarbamide market was valued at USD 226 million in 2025 and is projected to grow from USD 240 million in 2026 to reach USD 338 million by 2034, growing at a compound annual growth rate (CAGR) of 6.1% during the forecast period. Hydroxycarbamide, clinically known as hydroxyurea, is a foundational antineoplastic and antimetabolite medication that functions by inhibiting ribonucleotide reductase, a crucial enzyme for DNA synthesis. This mechanism positions it as a cornerstone therapy for several hematologic conditions. Its primary applications include the management of sickle cell disease, where it significantly reduces the frequency of painful crises and acute chest syndrome, as well as the treatment of specific cancers like chronic myelogenous leukemia, polycythemia vera, and essential thrombocythemia. Its established efficacy in cytoreduction and symptom management continues to underpin its critical importance in hematology and oncology. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/663/hydroxycarbamide-market-market

Tubular Metal Biliary Stents Market to Reach USD 510 Million by 2034 According to a newly published market research report by 24LifeSciences, global tubular metal biliary stents market is valued at USD 337 million in 2026 and is projected to reach USD 510 million by 2034, growing at a compound annual growth rate (CAGR) of 6.1% during the forecast period. Tubular metal biliary stents are self-expanding metallic mesh devices primarily used to maintain bile duct patency in patients suffering from malignant obstructions caused by pancreatic cancer or cholangiocarcinoma, as well as benign strictures. These minimally invasive implants are deployed via endoscopic retrograde cholangiopancreatography (ERCP) procedures to relieve jaundice, prevent life-threatening cholangitis, and significantly improve patients' quality of life. The market is primarily segmented into covered stentswhich feature a polymer membrane to prevent tumor ingrowthand uncovered stents, each offering distinct clinical advantages for specific patient populations. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/10403/tubular-metal-biliary-stents-market

Top 10 Companies Shaping the Global Parathyroid Disorders Market (2026–2034) According to a newly published market research report by 24LifeSciences, global parathyroid disorders market is valued at USD 2.1 billion in 2026 and is projected to reach USD 3.5 billion by 2034, growing at a compound annual growth rate (CAGR) of 5.8% during the forecast period. Parathyroid disorders are medical conditions resulting from the dysfunction of the parathyroid glands, four small glands located in the neck that regulate the body's calcium levels. These disorders lead to abnormal calcium levels in the blood, which can cause significant health issues such as brittle bones (osteoporosis), kidney stones, chronic fatigue, and muscle weakness. The primary disorders include hyperparathyroidism (overactive glands), hypoparathyroidism (underactive glands), and the rare parathyroid cancer. Market growth is primarily driven by an aging global population more susceptible to these conditions and the rising prevalence of chronic kidney disease (CKD), a major cause of secondary hyperparathyroidism. Furthermore, advancements in diagnostic techniques, such as more sensitive parathyroid hormone (PTH) assays, are facilitating earlier and more accurate detection. Key players like Amgen, with its calcimimetic drug Cinacalcet, and Abbott Laboratories, a leader in diagnostic solutions, are actively shaping the treatment landscape through innovation and strategic initiatives, contributing to market expansion. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9574/parathyroid-disorders-market

Dermatoscope Market to Reach USD 82.6 Million by 2032 | Growth Trends & Insights According to a newly published market research report by 24LifeSciences, global dermatoscope market is valued at USD 41.4 million in 2026 and is projected to reach USD 82.6 million by 2034, growing at a compound annual growth rate (CAGR) of 10.6% during the forecast period. A dermatoscope is a vital non-invasive diagnostic instrument used in dermatoscopy for examining skin lesions with enhanced visualization. This handheld device employs magnification and specialized lighting systems to reveal subsurface skin structures invisible to the naked eye. Modern dermatoscopes increasingly utilize polarized light technology which eliminates the need for contact fluids, allowing clinicians to examine pigment networks, vascular patterns, and other morphological features critical for accurate diagnosis of skin cancers like melanoma and various dermatological conditions. Its established role in improving diagnostic accuracy continues to underpin its importance in dermatological practice and primary care settings worldwide. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/6685/dermatoscope-market-market

Global Generic Oncology Drugs Market Size & Growth Drivers Through 2034 According to a newly published market research report by 24LifeSciences, global generic oncology drugs market is valued at USD 35.2 billion in 2026 and is projected to reach USD 54.1 billion by 2034, growing at a compound annual growth rate (CAGR) of 6.3% during the forecast period. Generic oncology drugs are bioequivalent versions of brand-name cancer medications used after patent expirations, providing the same active ingredients, dosage, strength, and administration routes as their innovators. These drugs are broadly categorized into small molecule drugs and large molecule drugs (biosimilars), playing a critical role in making cancer treatment affordable and accessible globally. Their established efficacy and cost-effectiveness continue to underpin their importance in oncology care, particularly amid rising healthcare cost pressures. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8833/generic-oncology-drugs-market